- Home
- STOK
as 05-09-2025 4:00pm EST
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 517.0M | IPO Year: | 2019 |
| Target Price: | $27.50 | AVG Volume (30 days): | 776.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.35 - $17.58 | Next Earning Date: | 05-20-2025 |
| Revenue: | $36,555,000 | Revenue Growth: | 316.34% |
| Revenue Growth (this year): | 27.8% | Revenue Growth (next year): | 9.53% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | May 1 '25 | Sell | $10.01 | 26,631 | $266,952.68 | 33,998 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Mar 18 '25 | Sell | $8.47 | 7,217 | $61,238.19 | 33,998 | |
| Kaye Edward M. MD | STOK | Director | Mar 18 '25 | Sell | $8.47 | 19,289 | $163,672.83 | 148,253 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Mar 18 '25 | Sell | $8.47 | 4,211 | $35,731.37 | 31,565 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Investor's Business Daily
9 days ago
Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?
Simply Wall St.
16 days ago
Is There An Opportunity With Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 49% Undervaluation?
Zacks
17 days ago
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
18 days ago
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?
Business Wire
a month ago
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Simply Wall St.
2 months ago
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Investopedia
2 months ago
Stoke Therapeutics Stock Slips as CEO Steps Down
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.